GlobeNewswire Inc | Feb 23, 2021 10:00AM EST

February 23, 2021

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links belowor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

QuantumScape Corporation (NYSE: QS)Class Period: November 27, 2020 - December 31, 2020Deadline: March 8, 2021For more info:www.bgandg.com/qsThe complaint alleges that throughout the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) that the Companys purported success related to its solid-state battery power, battery life, and energy density were significantly overstated; (2) that the Company is unlikely to be able to scale its technology to the multi-layer cell necessary to power electric vehicles; and (3) that, as a result of the foregoing, Defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Tricida, Inc. (NASDAQ: TCDA)Class Period: September 4, 2019-October 28, 2020Deadline: March 8, 2021For more info:www.bgandg.com/tcdaThe complaint alleges that throughout the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Tricida's NDA for veverimer was materially deficient; (2) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

GTT Communications, Inc.(NYSE: GTT)Class Period: May 5, 2016 - November 9, 2020Deadline: March 15, 2021For more info:www.bgandg.com/gttThe complaint alleges that throughout the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's internal controls suffered from issues related to the recording and reporting of Cost of Telecommunications Services; (2) the Company's previously reported Cost of Telecommunications was inaccurate or accounted for unsupported adjustments; (3) inadequate internal controls would result in delays in the Company's 10-Q quarterly reports; and (4) as a result of the foregoing, Defendants' public statements were materially false and/or misleading and/or lacked a reasonable basis.

Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com